InnovAge Holding Corp. Delivers Profitable Earnings Rebound

Innovage Holding Corp. ((INNV)) has held its Q2 earnings call. Read on for the main highlights of the call.

InnovAge Holding Corp.’s latest earnings call struck a cautiously upbeat tone, with management highlighting a solid return to profitability, strong revenue growth and improved cash generation. Executives emphasized that operational discipline and tighter cost control are paying off, even as de novo center losses, rising care costs and policy uncertainty remain important watchpoints for investors.

Revenue Growth and Enrollment Momentum

InnovAge reported Q2 revenue of $239.7 million, up 14.7% year over year and 1.5% sequentially, powered by higher member months and better capitation rates. Participant census reached about 8,010 at quarter‑end, roughly 7.1% above last year, supported by Medicaid reinstatements and steady enrollment trends.

Adjusted EBITDA Turnaround and Profitability

The quarter marked a clear profitability inflection, with adjusted EBITDA climbing to $22.2 million and margin reaching 9.2%, above the company’s 8%–9% target. That compares with a 2.8% margin a year ago and reflects sharper execution across medical cost management, operations and overhead.

Net Income Swings Back to the Black

Net income improved sharply to $11.8 million from a loss of $13.5 million in the prior year, equating to earnings of $0.08 per diluted share on roughly 136.4 million shares. The shift underscores how revenue growth, better unit economics and tighter costs are flowing through to the bottom line.

Member Months and Volume Drivers

Member months reached 23,960 in Q2, up about 7.9% year over year and 2% sequentially, reinforcing the revenue trajectory. Management pointed to successful work around Medicaid redeterminations and reinstatements as key contributors, though they acknowledged that retention and disenrollment still materially drive unit economics.

Contribution Margin and Cost Discipline

Center‑level contribution margin rose to $52.8 million, or 22% of revenue, about 430 basis points better than last year’s 17.7%. The gains stemmed from improved medical cost management, including lower permanent nursing facility utilization and savings from insourcing pharmacy services.

Balance Sheet Strength and Cash Generation

InnovAge closed the quarter with $83.2 million in cash and $42.8 million in short‑term investments against $69.9 million of debt, supported by $21.4 million of operating cash flow. With capital spending a modest $2.4 million, the company appears better positioned to fund growth while absorbing de novo and restructuring headwinds.

Operational Execution and Governance Changes

Management highlighted progress on revenue integrity, especially around Medicaid eligibility and redeterminations, alongside more standardized center operations and streamlined corporate G&A. Overhead expenses fell 5.3% versus last year and 12.1% from Q1, while governance changes at the board level aim to bolster oversight of strategy and risk.

De Novo Centers Remain a Drag

New centers, primarily in Tampa and Orlando, generated losses of $4.7 million in Q2 and are expected to contribute $11.5 million to $13.5 million in losses for fiscal 2026. While excluded from adjusted EBITDA, these de novo sites remain a real drag on reported operating results and will need scale and efficiency to turn accretive.

Rising Care Costs and Expense Pressures

Cost of care excluding depreciation and amortization rose 16.9% year over year to $74.9 million, reflecting higher wages, third‑party fees, pharmacy shipping and transportation costs. External provider spend also climbed to $112 million, up 3.8%, showing that the company’s cost wins are being partially offset by inflation in key care settings.

Wage, Restructuring and Labor Dynamics

Higher wage rates and reorganization‑related costs are pushing salaries, wages and benefits higher in the near term, even with some headcount reductions. Management framed these moves as necessary investments to stabilize operations and quality, but they acknowledged that labor and restructuring will weigh on margins before full benefits materialize.

Retention Challenges and Disenrollment Risk

Voluntary disenrollments remain a core area of concern, with management referencing annualized rates in a mid‑single‑digit to low‑teens range at different points. Such churn can erode member months, pressure revenue growth and dilute the fixed‑cost leverage that underpins PACE economics, making retention improvements a strategic priority.

Policy, Rate and State Process Uncertainty

Changes tied to the latest Medicare risk model and a proposed blended risk score create reimbursement uncertainty for InnovAge, even though only about 45% of its premium exposure is Medicare. The company also remains dependent on state‑level redetermination processes, where resource constraints and delays can affect enrollment timing and revenue recognition.

Seasonality and Clinical Cost Headwinds

Management warned that Q3 tends to be softer seasonally and that elevated flu incidence could boost utilization and squeeze margins. Rising unit costs in assisted living, permanent nursing facilities and inpatient care also pose a challenge, partly offsetting per‑participant cost improvements achieved elsewhere in the model.

Guidance and Management’s Outlook

InnovAge raised its fiscal 2026 outlook and now expects 92,900 to 95,700 member months, $925 million to $950 million in revenue and $70 million to $75 million of adjusted EBITDA, while holding its ending census view steady. The upgraded guide rests on first‑half outperformance, successful Medicaid reinstatements, stronger Medicaid rates and a phased impact from Medicare model changes.

InnovAge’s earnings call painted the picture of a business regaining its financial footing, with revenue growth, profitability and cash flow moving in the right direction. Investors will now watch whether management can sustain cost discipline, ramp de novo centers and navigate policy, wage and retention risks without derailing the company’s newly raised guidance trajectory.